Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer

By Michael Dabaie

Bristol Myers Squibb said the European Commission approved Opdivo for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer.

Bristol Myers said the approval is for patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy.

The approval is based on results from the Phase 3 CheckMate -577 trial, which demonstrated that treatment with Opdivo following neoadjuvant chemoradiotherapy and complete surgical resection doubled the primary objective of disease-free survival compared with placebo, the company said.

In May, Opdivo received approval from the U.S. Food and Drug Administration for adjuvant treatment of completely resected esophageal or GEJ cancer.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

07-30-21 0815ET